Business
REGENXBIO Reports Third Quarter 2021 Financial Results and Operational Highlights
ROCKVILLE, Md., Nov. 2, 2021 /PRNewswire/ -- Announced eye care collaboration with AbbVie to develop and commercialize RGX-314 AbbVie and REGENXBIO form a
About this update from Regenxbio Inc.
[{"type":"text","content":"ROCKVILLE, Md., Nov. 2, 2021 /PRNewswire/ --\nAnnounced eye care collaboration with AbbVie to develop and commercialize RGX-314 AbbVie and REGENXBIO form a strategic partnership combining eye care and gene therapy expertise REGENXBIO to receive $370 million upfront payment Transaction expected to close by end of 2021, subject to satisfaction of customary closing conditions, including applicable regulatory approvals Presented positive initial data from RGX-314 Phase II trials for the treatment of wet AMD and diabetic retinopathy using in-office suprachoroidal delivery In AAVIATE® trial for the treatment of wet AMD, observed treatment effect with stable visual acuity and retinal thickness and meaningful reduction in anti-VEGF treatment burden 33% of patients in ALTITUDE™ trial for the treatment of DR demonstrated a ≥2 step improvement from baseline on the ETDRS-DRSSOn track to file IND for RGX-202 for the treatment of Duchenne by end of 2021 Cohort 3 of the ongoing Phase I/II trial of RGX-121 for the treatment of patients up to 5 years old diagnosed with MPS II has been expanded to enroll up to 6 additional patients $533.5 million in cash, cash equivalents and marketable securities as of September 30, 2021 Conference call Tuesday, November 2nd at 4:30 p.m. ETREGENXBIO Inc. (Nasdaq: RGNX) today announced financial results for the third quarter ended September 30, 2021, and recent operational highlights.\n\"We are encouraged by the clinical profile emerging from ongoing clinical trials evaluating the suprachoroidal delivery of RGX-314 for the treatment of wet AMD and diabetic retinopathy. Preliminary data highlight the potential of one-time, in-office delivery of RGX-314 which could provide sustainable, long-term anti-VEGF protein production in the eye for patients,\" said Kenneth T. Mills, President and Chief Executive Officer of REGENXBIO. \"Moreover, our recently announced eye care collaboration with AbbVie, combining our AAV gene therapy expertise with AbbVie's global developmental and commercial infrastructure within eye care, will further support the broad potential of our RGX-314 program utilizing both subretinal and suprachoroidal delivery. We continue to expect this transaction to close by the end of this year.\"\nMr. Mills added: \"For the remainder of 2021, we are focused on continuing to enroll patients in the ATMOSPHERE...